Plenty of catalysts for Biocon over the next few months, say analysts

Topics Biocon

Rising almost 10 per cent in intra-day trade, shares of Biocon scaled an all-time high of Rs 455 apiece on Monday, before closing the day with minor gains. The Drug Controller General of India’s (DCGI’s) nod for the launch of Covid-19 treatment biologic Itolizumab (ALZUMAb) in an injectable form for emergency use, coupled with the company’s claim of its efficacy, constituted major triggers.  Analysts say Biocon’s product has an advantage and is to be used for patients suffering from moderate- to severe-respiratory distress. While many players have launched.....

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel
Key stories on business-standard.com are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.